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Obesity is one of the most prevalent metabolic diseases in the Western world and correlates directly with insulin resistance,
which may ultimately culminate in type 2 diabetes (T2D). We sought to ascertain whether the human metalloproteinase A
Disintegrin and Metalloproteinase 19 (ADAM19) correlates with parameters of the metabolic syndrome in humans and mice. To
determine the potential novel role of ADAM19 in the metabolic syndrome, we first conducted microarray studies on peripheral
blood mononuclear cells from a well-characterised human cohort. Secondly, we examined the expression of ADAM19 in liver
and gonadal white adipose tissue using an in vivo diet induced obesity mouse model. Finally, we investigated the effect of
neutralising ADAM19 on diet induced weight gain, insulin resistance in vivo, and liver TNF-𝛼 levels. Significantly, we show that, in
humans, ADAM19 strongly correlates with parameters of the metabolic syndrome, particularly BMI, relative fat, HOMA-IR, and
triglycerides. Furthermore, we identified that ADAM19 expression was markedly increased in the liver and gonadal white adipose
tissue of obese and T2D mice. Excitingly, we demonstrate in our diet induced obesity mouse model that neutralising ADAM19
therapy results in weight loss, improves insulin sensitivity, and reduces liver TNF-𝛼 levels. Our novel data suggest that ADAM19 is
pro-obesogenic and enhances insulin resistance. Therefore, neutralisation of ADAM19 may be a potential therapeutic approach to
treat obesity and T2D.
1. Introduction
Obesity is one of the most prevalent metabolic diseases in
the Western world and correlates with glucose intolerance,
insulin resistance, dyslipidemia, and cardiovascular disease.
These metabolic parameters may ultimately culminate in
pancreatic beta cell failure and type 2 diabetes (T2D) [1].
As the financial and social burden of obesity escalates, it is
crucial to develop new human therapeutics to alleviate the
adverse consequences of the metabolic syndrome.
There has been growing interest in the role of metallo-
proteinases or ADisintegrin andMetalloproteinase (ADAM)
proteins, in metabolic disorders. ADAMs are proteolytic
enzymes which regulate cell phenotype through affecting
cell adhesion, migration, proteolysis, and signalling [2]. Our
group was the first to identify that ADAM28 is elevated in
humanswith themetabolic syndrome and is a novel sheddase
of human tumour necrosis factor-𝛼 (TNF-𝛼) [3]. Relevantly,
TNF-𝛼 is amajor proinflammatory cytokine implicated in the
metabolic syndrome [4, 5] and it is well established that TNF-
𝛼 induces insulin resistance [6, 7]. Similarly, the activity of
ADAM17, also known as TNF-𝛼 converting enzyme (TACE),
correlates with insulin resistance [8, 9] and administration
of TACE inhibitors to humans in clinical trial settings has
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proven to effectively decrease inflammatory mediators [10].
Interestingly, our group and others have shown that TNF-
𝛼 is also a substrate for ADAM19 [11–13] and therefore it is
possible that ADAM19 may have an underlying role in the
pathogenesis of obesity and T2D.
ADAM19, also known as meltrin 𝛽, was identified and
characterised by our team [14, 15] and others [16]. ADAM19
contains several complex domains, including a pro-domain,
metalloproteinase domain, disintegrin domain, cysteine-rich
domain, epidermal growth factor-like domain, transmem-
brane domain, and cytoplasmic tail domain [15]. Of most
relevance, the metalloproteinase domain of ADAM19 is
known to be involved in extracellular matrix breakdown and
reconstruction [14]. One of the most important functions
carried out by the metalloproteinase domain of ADAM19
is the catalytically mediated ectodomain shedding of sub-
strates [14] such as TNF-𝛼. ADAM19 is expressed in numer-
ous metabolically relevant cell types and tissues, including
peripheral bloodmononuclear cells, liver, and skeletal muscle
[14]. Furthermore, ADAM19 has been linked to numerous
diseases [15] and serves important biological functions in
embryogenesis [17], cardiovascular system development [18],
and skeletal muscle adaptation [19]. Our study is the first to
examine the role of ADAM19 in obesity, insulin resistance,
and T2D.
In this study, we hypothesised that ADAM19 is associated
with the metabolic syndrome in humans and mice. The out-
comes of this study provide novel insights into the ADAM19-
mediated pathogenesis of obesity, insulin resistance, and
T2D.
2. Materials and Methods
2.1. Human Microarray for the Identification of Metallopro-
teinases Involved in Obesity and T2D. RNA samples (from
peripheral blood mononuclear cells) were obtained from the
San Antonio Family Heart Study (SAFHS) (𝑛 = 1240), a
study of risk factors for cardiovascular disease in Mexican
Americans living in and around San Antonio, Texas [20].
The SAFHS is a large family-based genetic epidemiological
study including 1431 individuals from 42 extended families
at baseline. Individuals from large randomly selected, multi-
generational pedigrees were sampled independent of their
phenotype or the presence or absence of disease. All partic-
ipants in the SAFHS provided informed consent. The study
and all protocols were approved by the Institutional Review
Board at the University of Texas Health Science Centre at San
Antonio (San Antonio, TX). Gene expression profiles were
generated using microarrays, and data processing steps and
quality control are as described previously [20].
2.2. Animals. In our first mouse cohort, eight-week-old male
specific pathogen-free C57BL6/J mice were obtained from
the Animal Resources Centre (ARC, Perth). Mice were
administered a normal chow (14.3MJ/kg, 76% of kJ from
carbohydrate, 5% from fat, 19% from protein; Specialty Feeds,
Glen Forrest, WA, Australia) or high fat diet, HFD (19MJ/kg,
35% of kJ from carbohydrate, 42% from fat, 23% from
protein; Specialty Feeds, Glen Forrest, WA, Australia) for 12
weeks. Body weights were recorded on a weekly basis. At
the end of the experiment, mice were sacrificed and the liver
and gonadal white adipose tissue was collected for paraffin
embedding for immunohistochemistry and snap frozen in
liquid nitrogen for mRNA studies.
In our second cohort of mice, eight-week-old male
specific pathogen-freeC57BL6/Jmicewere obtained from the
Animal Resources Centre (ARC, Perth). Mice were placed on
different diet/antibody treatment regimes: (1) standard chow
(𝑛 = 9); (2) high fat diet, administered rabbit pre-immune
IgG (𝑛 = 3); (3) high fat diet, administered rabbit ADAM19
neutralising antibody (𝑛 = 3). Neutralising antibodies were
administered at week 10 of the dietary regiment as ADAM19
protein is increased at this time-point in tissues such as liver.
Mice received 100 𝜇g of antibody every 2 days via tail vein
for the final two weeks of feeding. Insulin tolerance tests
(ITT; 0.5U/kg) and glucose tolerance tests (GTT; 1 g/kg) were
performed at the end of week 12. Body weight measurements
were determined each week. Mice were sacrificed at the end
of the experiment and their blood was collected for serum
and livers were collected for paraffin embedding.
2.3. ADAM19 Neutralising Antibody. The rabbit ADAM19
neutralising antibody [pAb361] used for our experiments is
well characterised by our team [21, 22].
2.4. ADAM19 Immunohistochemistry on Murine Liver. Liver
tissue of mice fed with standard chow or HFD was fixed
in 4% paraformaldehyde and paraffin embedded. Standard
immunohistochemistry procedures were conducted, includ-
ing antigen retrieval and incubations with primary antibody
(rabbit anti-hADAM19 disintegrin domain IgG (pAb362))
at a 1 : 200 dilution [21, 23]. Sections were visualised with
diaminobenzidine (DAB; DAKO).
2.5. Adam19 and Tnf-𝛼 mRNA Expression Studies in Livers
and/or Gonadal White Adipose Tissue of Mice Fed a HFD.
RNA from livers ofmice fed aHFDwas extracted using Trizol
reagent (Invitrogen) and cDNA synthesis was performed
using the High Capacity RNA-to-cDNA kit (Applied Biosys-
tems). Real-time PCR to determine the mRNA abundance of
mouse Tnf-𝛼 and Hprt (house-keeper gene) was performed
using a Rotor-gene real-time PCR machine (Qiagen) using
predeveloped TaqMan probe (FAM labelled) and primer
sets for mouse Tnf-𝛼 (Mm00443260 g1), mouse Adam19
(Mm00477337 m1), and mouse Hprt (Mm01545399 m1)
(Applied Biosystems). Quantitation was conducted as previ-
ously described [24].
2.6. TNF-𝛼 ELISA on Murine Liver Protein. Liver tissue
was homogenised in cytosolic extraction buffer containing
phosphatase and protease inhibitors. Protein levels were
determined using a Bradford protein assay and TNF-𝛼
was measured in lysates using a mouse TNF-𝛼 ELISA
(http://www.elisakit.com/).
2.7. Statistics. Associations between ADAM19 lymphocyte-
derived gene expression and clinical parameters in the
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Table 1: Parameters of the metabolic syndrome are associated with
high ADAM19 expression in human peripheral blood mononuclear
cells (𝑛 = 1240).
Parameter 𝑝 value Direction of correlation
Fasting insulin 0.003 Positive
BMI 0.000046 Positive
HDL cholesterol 0.000065 Negative




C-reactive protein 0.05 Positive
IL-1𝛽 0.05 Positive
BMI: bodymass index; HDL: high-density lipoprotein; TNF: tumor necrosis
factor; IL: interleukin.
Mexican American pedigrees were determined using a lin-
ear mixed model allowing for residual non-independence
amongst family members as a function of their genetic
relationships. A likelihood ratio statistic was utilised to
test whether ADAM19 expression significantly predicted a
relevant standard clinical parameter (fasting insulin, BMI,
HDL-C, relative fat mass, HOMA-IR index of insulin resis-
tance, TNF-𝛼, triglycerides, C-reactive protein, and IL-1𝛽).
Other primary covariates were simultaneously controlled for
including sex and age. All analyses were performed using the
statistical package, SOLAR.
All in vivo results are expressed as the mean + and/or −
standard error of the mean (SEM). Data were analysed for
differences by Student's 𝑡-test for unpaired samples where
appropriate. Data was considered to be statistically significant
when 𝑝 ≤ 0.05.
3. Results
3.1. ADAM19 Expression in Human Blood Mononuclear Cells
Is a Novel Marker of the Metabolic Syndrome. Here we use
a large human cohort, the San Antonio Family Heart Study
(SAFHS), which is well characterised for T2D and cardio-
vascular disease, that has also been extensively genetically
analysed and carries fullmicroarray-based genomewide gene
expression profiles on 1,240 individuals. This dataset was
filtered to identify novel metalloproteinases involved in the
development of obesity and type 2 diabetes. We have found
that high-level expression of ADAM19 in blood mononu-
clear cells from the SAFHS cohort correlated strongly with
parameters of the metabolic syndrome and in particular
BMI, relative fat, index of insulin resistance (HOMA-IR), and
triglycerides (Table 1). In addition, ADAM19 expression in
the SAFHS cohort also strongly correlatedwith circulatingC-
reactive protein, IL-1𝛽, and TNF-𝛼 levels (Table 1). The latter
is relevant as TNF-𝛼 is a substrate for ADAM19.These highly
significant clinically relevant observations suggest a role for
ADAM19 in the regulation of human metabolism.
3.2. ADAM19 and Its Substrate TNF-𝛼 Are Elevated in Liver
Biopsies from Our HFD-Fed Mice. To complement our clini-
cal observations, we explored ADAM19 expression and activ-
ity in animal models. Mice were weighed weekly to confirm
obesity (Figure 1(a)). T2D was verified by insulin tolerance
tests and glucose tolerance tests at the end of the experiment
(Supplementary Figure 3 in SupplementaryMaterial available
online at https://doi.org/10.1155/2017/7281986) as previously
conducted by our group [25]. We next investigated ADAM19
protein expression in liver, as it is an organ that is involved
in lipid and glucose metabolism [26]. It has been previously
reported that there is low expression of ADAM19 in murine
liver [16].We found that ADAM19 protein levels are increased
in the highly steatotic livers of mice that have HFD-induced
obesity and T2D compared to mice fed a normal chow
(Figures 1(b) and 1(c)).
As previously mentioned, TNF-𝛼 is a proinflammatory
cytokine involved in the metabolic syndrome and is a known
substrate for ADAM19. Given that ADAM19 gene expression
in human lymphocytes correlates with TNF-𝛼 protein level in
the blood stream (Table 1) and ADAM19 protein is elevated
in the liver of mice fed a HFD, we also wanted to determine
whether Tnf-𝛼 gene expression is increased in the livers of
our cohort of mice fed a HFD.We found that mRNA levels of
Tnf-𝛼 are elevated in liver (Figure 2) biopsies from our mice
that have HFD-induced obesity and T2D compared to chow
fed mice. In addition, we also highlighted that both Adam19
(Figure 3(a)) and Tnf-𝛼 (Figure 3(b)) gene expression were
increased in gonadal white adipose tissue from HFD mice
compared to chow fed mice.
3.3. Neutralising ADAM19 Causes Weight Loss in HFD-Fed
Mice. Weare the first group to assess the effect of neutralising
ADAM19 activity in vivo on the parameters of the metabolic
syndrome.Through our ADAM19 neutralisation experiment,
we found in our obese and T2D mice that neutralising
ADAM19 activity minimises the accumulation of gonadal
adipose tissue compared with mice administered the IgG
control antibody (Figure 4).
Secondly, we showed for the first time that HFD-fed
mice administered ADAM19 neutralising antibody lost a
significant amount of weight when compared with mice that
were administered rabbit IgG control antibody injections
(𝑝 < 0.02) (Figure 5). Mice were monitored daily during
antibody administrations and both groups displayed normal
behaviour, posture, response to touch, and healthy coats.This
novel finding provides evidence that neutralising antibody
directed against the metalloproteinase domain of ADAM19
could be a potential therapeutic to alleviate symptoms of the
metabolic syndrome.
3.4. Neutralising ADAM19 Improves Insulin Sensitivity in
HFD-Fed Mice. Given that obese and T2D mice adminis-
tered ADAM19 neutralising antibody lost weight, we were
curious to explore if these mice were also more insulin
sensitive. We performed an insulin tolerance test (ITT) at
the end of the experiment. Despite the ADAM19 neutralising
antibody group commencing the experiment with higher
fasting glucose compared to the rabbit IgG group, the group













































Figure 1: High fat diet induces obesity and elevates ADAM19 expression in mice. Mice fed a high fat diet gained weight (a); 𝑛 = 14–18/group.
Representative photomicrographs of ADAM19 protein expression in livers from mice fed either a normal chow (b) or high fat diet (c).































Figure 2: Elevated TNF-𝛼 mRNA levels in the livers of mice on a
high fat diet for 12 weeks. ∗𝑝 < 0.05; 𝑛 = 14–17mice/group.
administered with ADAM19 neutralising antibody had lower
blood glucose levels by the conclusion of the experiment
(Figure 6). This finding indicated that neutralising ADAM19
activity improved insulin sensitivity in HFD-fed mice, which
correlated with weight loss. This novel data suggests that the
ADAM19 metalloproteinase domain may play a crucial role
in obesity, insulin resistance, and T2D.
3.5. Neutralising ADAM19 Reduces TNF-𝛼 Protein Levels but
Does Not Effect ADAM19 Protein Expression in Livers from
HFD-FedMice. As ADAM19 is a sheddase of TNF-𝛼 protein,
we measured the TNF-𝛼 protein levels by ELISA in the livers
of mice treated with either rabbit IgG control antibody or
ADAM19 neutralising antibody. We found that neutralising
ADAM19 activity resulted in reduced TNF-𝛼 protein levels
in the liver (Figure 7). The TNF-𝛼 protein may be cleaved or
cytoplasmic derived TNF-𝛼.
We also examinedwhether neutralisingADAM19 activity
promoted ADAM19 expression to be elevated in a compen-
satory manner in livers from obese and T2D mice. We per-
formed ADAM19 immunohistochemistry on livers of HFD-
fed mice administered either rabbit IgG control antibody or
ADAM19 neutralising antibody. We found that the level of
expression did not differ between mice administered rabbit
IgG control or ADAM19 neutralising antibody (Figure 8).
Therefore, neutralising ADAM19 activity does not result in
a compensatory upregulation of ADAM19 protein expression
in the livers from obese and T2D mice.
3.6. In Vivo siRNA Mediated Knockdown of ADAM19. To
support our insulin sensitivity findings from the ADAM19
neutralisation experiments, we then conducted experiments








































































Figure 3: Elevated Adam19 (a) and Tnf-𝛼 (b) mRNA levels in gonadal white adipose tissue of mice on a high fat diet for 16 weeks. ∗𝑝 < 0.05;
𝑛 = 7-8 mice/group.
(a) (b)
Figure 4: Neutralisation of ADAM19 reduces high fat diet induced obesity. Representative photographs of HFD-fed mice administered
with either rabbit IgG (a) or ADAM19 neutralising antibody (b). Mice administered rabbit IgG possessed increased gonadal adipose tissue
compared to mice administered ADAM19 neutralising antibody.
using siSTABLE siRNA targeting mouse ADAM19. We
demonstrated that we could effectively knock downADAM19
in vitro (Supplementary Figure 1) and in vivo (Supple-
mentary Figure 2(A)). We highlighted that HFD-fed mice
administered siSTABLE siRNA targeting ADAM19 possessed
increased insulin sensitivity compared to HFD-fed mice
administered non-targeting siSTABLE siRNA (Supplemen-
tary Figure 2(B)).
4. Discussion
Our group is the first to examine the role of ADAM19 in
obesity and T2D. We found that high-level expression of
ADAM19 in lymphocytes from the SAFHS cohort strongly
correlated with the parameters of themetabolic syndrome. In
particular, ADAM19 expression was significantly correlated
with BMI, relative fat, HOMA-IR, and TNF-𝛼 levels. These
significant and novel clinical observations provided strong
support for a role of ADAM19 in the regulation of human
obesity, insulin resistance, and T2D.This data prompted us to
further evaluate the role of ADAM19 using our in vivo obese
and T2D mouse model. We found that ADAM19 protein
expression is elevated in highly steatotic liver and gonadal
white adipose tissue of obese and T2Dmice.This is extremely
interesting as it has been previously reported thatmurine liver
has low ADAM19 expression [16]. In our in vivo study, mice
fed standard chow also had low ADAM19 expression.
We showed that TNF-𝛼 mRNA levels were significantly
increased in liver and gonadal white adipose tissue of obese
and T2D mice. TNF-𝛼 is a major proinflammatory cytokine
implicated in the metabolic syndrome [4, 5], particularly
insulin resistance [6, 7]. As TNF-𝛼 is a substrate for ADAM19
[11–13], we hypothesise that the shedding of TNF-𝛼 by the
ADAM19 metalloproteinase domain potentially exacerbates
the pathogenesis of the metabolic syndrome. In support of
this hypothesis, we were able to demonstrate in our in vivo









































Figure 5: Elevated weight loss after administration of ADAM19
neutralising antibody. Mice which were administered ADAM19
neutralising antibody lost a significant amount of weight when
compared with mice administered the rabbit IgG control antibody.
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Figure 6: Neutralisation of ADAM19 improves insulin sensitivity in
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Figure 7: Neutralisation of ADAM19 reduces liver TNF-𝛼 levels in
HFD-fed mice. Mean + SEM; ∗𝑝 = 0.05; 𝑛 = 3mice/group.
studies in HFD-fed mice that neutralisation of ADAM19
resulted in a marked reduction in TNF-𝛼 protein in the liver.
This TNF-𝛼 protein may be cleaved or cytoplasmic derived.
We examined whether neutralising themetalloproteinase
domain of ADAM19 would reduce the parameters of the
metabolic syndrome in vivo. We are the first to show that
neutralising ADAM19 activity reduces high fat diet induced
obesity. In addition, neutralisation of ADAM19 promotes
insulin sensitivity in obese and T2D mice. To support this
finding, we demonstrated that HFD-fed mice administered
siSTABLE siRNA targeting ADAM19 possessed increased
insulin sensitivity compared to HFD-fed mice administered
nontargeting siSTABLE siRNA. Combined, this novel data
provides evidence that neutralising antibody directed against
the metalloproteinase domain of ADAM19 could be a poten-
tial therapeutic to alleviate symptoms of the metabolic syn-
drome. Currently, there are no specific ADAM19 pharmaco-
logical inhibitors available and hence ADAM19 neutralising
antibodies appear to be the most realistic available therapy to
inhibit the function of ADAM19.
Targeting ADAMs with pharmacological inhibitors is
being investigated as a potential therapeutic strategy for
inflammatory diseases. The highly selective and orally active
TACE (ADAM17) inhibitor, Ro 32-7315, has highlighted
the reality that metalloproteinase inhibitors may inhibit
inflammation induced TNF-𝛼 shedding and can be used
safely in humans [27]. Of utmost importance is the fact
that administration of TACE inhibitors to humans in clinical
trial settings has proven to effectively decrease inflammatory
mediators [10]. We used ADAM19 neutralising antibody in
our current study which is a clinically relevant therapy.
Neutralising antibody that targets TNF-𝛼 is currently used
for rheumatoid arthritis in animal models and humans [28,
29]. Currently, there are a limited number of studies which
utilise neutralising antibodies that target metalloproteinases
in human disease [30–32]. Therefore, studies like ours are
very important and may ignite further interest in the area.
Future studies should aim to examine potential upstream
regulators of the increase of ADAM19 protein expression in
relation to the metabolic syndrome in humans and mice.
A study by Keating et al. (2006) identified that ADAM19
is induced by transforming growth factor beta 1 (TGF-𝛽1)
[33]. Human studies have shown that TGF-𝛽1 is positively
correlatedwith BMI [34] and increased plasma levels of TGF-
𝛽1 were reported in T2D [35]. Yadav et al. (2011) observed a
significant correlation between TGF-𝛽1 levels and adiposity
in humans and rodents, and inhibiting TGF-𝛽1 signalling
protected mice from obesity, hepatic steatosis, and diabetes
[36]. It would be intriguing to investigate the effect of TGF-
𝛽1 on ADAM19 expression and activation in our mouse
model of obesity and T2D. Another interesting potential
regulator of ADAM19 is furin. Our team previously reported
that the protein furin activates ADAM19 by binding to
and cleaving the prodomain of ADAM19 [37]. Relevantly, a
polymorphism in the furin gene (rs17514846) has been shown
to be significantly associated with hypertriglyceridemia and
the metabolic syndrome [38, 39]. It would be insightful
to ascertain whether furin protein levels are elevated in
human patients with the metabolic syndrome and whether
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Figure 8: Neutralising ADAM19 does not affect the expression of ADAM19 in the liver. Representative photomicrographs showing ADAM19
immunohistochemistry performed on livers fromHFD-fedmice administered either rabbit IgG control (a) or ADAM19 neutralising antibody
(b). ADAM19 staining is cytoplasmic and brown in colour. 200x objective.
the binding of furin to ADAM19 pathogenically activates
ADAM19 in vivo.
Whilst discussing potential regulators of ADAM19, it
is relevant to also consider what transcriptionally controls
ADAM19 expression in obesity and T2D. Putative binding
sites for the transcription factors Sp1, Sp3, NF-kappaB, and
VDR have already been identified in the ADAM19 gene [40].
If Sp1, Sp3, NF-kappaB, and VDR are increased in obese and
T2D subjects, then this could be amechanism underlying the
elevated expression of ADAM19 in the metabolic syndrome.
5. Conclusion
Our exciting findings highlight that elevated ADAM19 pro-
tein expression is associated with the parameters of the
metabolic syndrome in humans and mice. We identified for
the first time that neutralising the ADAM19 metallopro-
teinase domain reduced high fat diet induced obesity and
improved insulin sensitivity in obese and T2D mice. These
novel results provide evidence that neutralising antibody
directed against the metalloproteinase domain of ADAM19
could be a potential therapy for anti-obesity agents.
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